Medical Science Liaisons
Find and connect with your Medical Affairs Contact, also known as Medical Science Liaison (MSL), in your region and specialty.
Independent Medical Education (IME)
Sumitomo Pharma America, Inc. is committed to supporting Independent Medical Education (IME) programs that are objective, fair-balanced, unbiased, and scientifically rigorous. IME grant funding may be requested to support valuable medical, scientific, and educational information or activities (both accredited and nonaccredited) directed at health care professionals, patients, or caregivers.
Eligible Requestors:
- Medical Centers/Hospitals
- Medical Schools/Educational Institutions
- Professional Medical Societies and Associations
- Medical Education Companies
Educational Areas of Interest
Sumitomo Pharma America, Inc. considers IME requests that align with our focus areas, which may include:
Investigator-Initiated Studies (IIS) and Collaborative Research
Sumitomo Pharma America, Inc. is committed to advancing scientific knowledge and improving outcomes through collaboration with the global research community.
Our Investigator-Initiated Studies (IIS) and Collaborative Research programs support high-quality, ethically conducted research that aligns with our scientific objectives and enhances understanding of our products, technologies, and disease areas of interest.
Through these programs, qualified investigators and institutions may propose independent research or collaborative initiatives designed to generate clinical or scientific insights.
Investigator-Initiated Studies (IIS)
Investigator-Initiated Studies must be unsolicited and are proposed, designed, and conducted by external investigators or institutions, defined as the “sponsor”. The sponsor maintains full responsibility for study oversight, regulatory compliance, and data integrity. Sumitomo Pharma America, Inc. may provide financial support and/or product supply for IIS that meet predefined scientific and strategic criteria. The terms of each IIS are defined through a formal agreement. All IIS support is provided in accordance with applicable laws, regulations, and ethical standards.
Collaborative Research
Collaborative Research consists of joint scientific engagement between Sumitomo Pharma America, Inc. and external investigators or institutions, defined as the sponsor. These studies are typically characterized by shared scientific objectives and may include collaborative study designs, execution, or analysis. The nature of the collaboration, including roles and responsibilities, is defined through a formal agreement. All collaborations are conducted with transparency and in compliance with applicable ethical and regulatory standards.
Research Focus Areas
Sumitomo Pharma America, Inc. considers IIS and collaborative research requests that align with our focus areas, which may include:
Medical Sponsorships and Patient Advocacy Support
Medical Sponsorships
Sumitomo Pharma America, Inc. supports medical sponsorships that are non-promotional in nature and relate to disease state(s), medical conditions(s), or other topics relevant to Sumitomo Pharma America, Inc.’s therapeutic areas of interest.
Patient Advocacy Support
Sumitomo Pharma America, Inc. is dedicated to partnering with stakeholders to increase patient access to medicine, advance science that matters most to the patient communities we serve, and reimagine what is possible as we pursue unprecedented medical innovation.
Educational Focus Areas
Sumitomo Pharma America, Inc. considers medical sponsorships and patient advocacy requests that align with our focus areas, which may include:
- Acute Myeloid Leukemia
- Myelofibrosis
- Pediatric Congenital Athymia
- Prostate Cancer
- Endometriosis
- Uterine fibroids
- Overactive bladder
- Overactive bladder being treated for BPH
BPH, benign prostatic hyperplasia.
Application Requirements and Process
1. Submission
Requests for any category of research grant can be submitted via the Grants Portal . All submissions for IME, medical sponsorships, and patient advocacy must be made 60 days prior to the start date of the activity.
2. Review
Submissions are reviewed by the Sumitomo Pharma America, Inc. Scientific Review Committee.
3. Full Research Protocol
For IIS and collaborative research proposals only: Approved concepts will require the submission of a full research protocol for final review.
Grants Portal
To learn more and submit your application, please visit our Grants Portal. Note that submission of a proposal does not guarantee funding or support. Approved studies/programs require execution of the appropriate legal and financial agreements before initiation.
Contact Us
Sign Up for Updates
Stay informed and stay current with updates delivered directly to your inbox.
Medical Information
Submit a request for more information.
+ 1 (800) 739-0565Monday - Friday, 8 AM - 8 PM ET
Report an Adverse Event or Product Complaint
Please report any side effects related to any Sumitomo Pharma America, Inc. medication by contacting us. You may also contact the US Food and Drug Administration (FDA) directly by visiting www.fda.gov/Safety/MedWatch or calling 1-800-FDA-1088.